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revealed a strong graded mortality relationship (Range: 1 .O to 23.1%, p c.0001, c-statis- 1.43). This study confirms, in a large unselected cohort of HR-pts with AMI, that D is a 
tic 0.73). The predidive capacity of the TRI was particularly strong in lhose receiving rep- significant independent predictor of poor prognosis. Neverthless, pts with D are often 
erfusion therapy (STEMI-IRS, Fig A). Moreover, in patients with NSTEMI, the risk index undertreated with aggressive mechanical or pharmacological therapy. 
also revealed a significant graded relationship with mortality (Fig 6). 
Conclusions: A simple risk index from baseline clinical variables routinely obtained at 
the first patient encounter predicted mortality in a heterogeneous group of patients pre- a l-I=*- 
senting with STEMI or NSTEMI. Despite differences in syndrome pathophysiology, this _M”R, 
risk index may prove valuable in the assessment of patients with STEMI or NSTEMI. Ln 
1125-97 Thrombolysis in Myocardial Infarction Risk Score and 
ST Resolution Are Independent Predictors of Mortality 
1125-99 - Unraveling the Spectrum of Left Bundle Branch Block in 
Acute Myocaridal Infarction: Insights From ASSENT 3 
Francoise Boutot Jean Marie Caussanel, Emmanuel Pereira. Kolia Milojevic, Jean Marc 
Bayer. Yves Lambed, Versailles Hospital, Le Chesnay. France 
Background : Previous studies confirmed ST segment resolution (RST) during fibrinolyijc 
therapy (FT) for ST elevation myocardial infarction as a convenient marker of reperfusion 
correlated to TIMI flow grade and TIMI myocardial perfusion grade. The RST at 60, 90 
and 160 min after repedusion therapy is known to identify low mortality group of 
patients.The TIMI risk score is a clinical, bedside, risk score developped to predrct 
STEMI 30 days mortality. 
Objectives : The aim of this study is to assess the relationship between TIMI risk score 
and 60 min RST. 
Method : A cohort of 726 patients were given pre-hospital FT for STEMI (pain to FT, 
mean time 120 min). ECG was performed prior starting FT (baseline ECG) and 60 min 
later. ECG were analized to isolate two classes of RST: no or worsening RST (~30%) 
and partial or complete RST ()=30%). TIMI risk score was calculated at pre-hospital pre- 
sentation. 30 days mortality was investigated for each class of RST and each level of 
TIMI risk score. 
Results: The results are shown in the table below, and expressed in number of patients. 
TIMI risk score and 60 min RST are independent 30 days mortality markers(p>0.05). 
Conclusion : The absence of relationship between TIMI risk score and 60 min RST for 
STEMI patients suggests that RST should be taken into account as an independent vari- 
able in a new scoring system. 
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Death No RST RST Total 
1 29 71 106 
4 76 120 196 
5 41 a0 121 
9 39 79 113 
12 39 50 a9 
6 22 26 48 
5 14 14 28 
4 11 7 ia 
5 a 7 15 
51 279 449 728 
Hassam F. Al-Faleh, Yuling Fu, Galen S. Wagner, Shaun G. Goodman, E. Sgarbossa, 
Christopher B. Granger, Frans J. Van de Wed, Lars Wakentin, Paul W. Armstrong, For 
the ASSENT 3 Investigators, University of Alberta, Edmonton, AB. Canada 
Left bundle branch block (LBBB) complicates AMI diagnosis. Sgarbossa’s criteria devel- 
oped from GUSTO 1 to surmount this diagnostic challenge but have not been previously 
validated in a clinical trial. We evaluated their utility in the diagnosis and rusk stratifk?atlon 
of AMI patients (pts) in ASSENT 3. Methods: Baseline ECGs of ASSENT 3 pts were 
reviewed for LBBB by blinded core labs. Sequential ECGs (baselme, 60, 160 min & dis- 
charge) of LBBB pts were scored using Sgarbossa’s criteria (O-5) for AMI diagnosis. 
Results: 92(1.5%) pts had LBBB on baseline ECG: their 30-day death vs those without 
LBBB (n= 5932) was 14.1% vs 5.6% respectively (p=O.O03). More pts without peak CK 
>= 2x upper normal limit (UNL) had LBBB than those without LBBB (33.3% vs. 15.7%, 
p<O.OOl). Among 75 LBBB pts with peak CK data available, 30 day death tended to be 
lower among pts without peak CK rise than those with CK rise (4% versus la%, p=O.15). 
The table shows Sgarbossa’s score of >= 3 distribution (highly suggests AMI in the pres- 
ence of LBBB) and mortality. Sequenttal ECGs revealed that among 25 LBEB pts without 
peak CK rise, 15 pts did not have acute Ml on admission. 
Sgarbossa score ~3 Sgarbossa score <3 P value 
N=26 N=47 
Peak CK <2x 2 (7.2%) 23 (46.9%) <O.OOi 
Peak GK s=2x and 7 (14.9%) 
<=3x 
PeakCK>Bxandc=Sx 3 (10.7%) 7 (14.9%) 
Peak CK >5x 23 (62.1%) 10 (21.3%) 
30 day mortakty 6/28 (21.4%) 4147 (8.5%) 0.161 
Conclusion: Our findings validate the utrlity of Sgarbossa’s cntena for diagnosing AMI III 
the setting of LBBB. Sgarbossa’s criteria provide a sample and practical diagnostic 
approach to optimize risk- benefit of acute therapy in this diagnostically challenging 
group and contribute usefully to risk stratrfication in this high nsk population. 
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1125-98 One-Year Outcome of High-Risk Patients With Acute 
Myocardial Infarction With or Without Diabetes: Data 
1126 
From the MISTRAL Study 
Unstable Angina/Acute Myocardial 
Infarction: Prognosis 
Samuele Baldasseroni, Giuseppe Steffenino, Francesco Chiarella, Giovanni Maria 
Santoro, Antonio L. Bartorelli, Maria Luisa Laudisa, Donata Lucci. Aldo P. Maggioni, on 
behalf of MISTRAL Investigators, ANMCO Research Center, Florence, Italy 
Pts with diabetes (D) have more often severe coronary arteriosclerosis with high risk 
IHR) of AMI and cardiac death. We studied in-hosoital and I-Year outcomes of HR ots 
Aith’AMI with or without D treated with reperfusion therapy (thrombolysis or primary-P&) 
or drua theraw. 2227 HR-ots with AMI <I2 h were recruited at 17 centres wrth. and 30 
without, feasibility of performing primary PCI (classified at HR having21 of the following 
characteristics: female r70 y, diabetic >70 y, Killip class >I, SBP <IO0 mmHg and heart 
rate >lOO b/m, z-4 leads with ST deviation, previous Q-wave AMI, contraindication to 
thrombolysis). 1795 pts (60.6%) had not D and 432 pts (19.4%) were diabetic: pts with D 
were more often females, older, with a history of cardiovascular disease, arrhythmias 
during hospital stay and heart failure at entry. Pts with D were less treated with reperfu- 
sion therapy (74.3% vs 63.0%, p<O.OOOi) and with betablockers at discharge (41.2% vs 
49.5%, p<O.O05). One year mortality and combined end-point (death+reAMl+heart fail- 
ure+angina) are showed in the figure. When we adjusted the 1 -year outcomes for all clin- 
ical, haemodynamic variables and therapy, D remained an independent prognostic 
predictor (death OR: 1.54, 95%CI 1.13-2.09: combined end-point OR: 1.13, 95%CI 0.69- 
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1126-100 Increase in Mortality of Patients Discharged With the 
Diagnosis of Acute Myocardial Infarction Between 1986 
and 1996 
John 6. Kostis, Alan C. Wilson, Janet Lawrence-Nelson, Rajiv Ranjan, Nora M. 
Cosgrove, Clifton R. Lacy, Pearl D’Sa, UMDNJ-Robert Wood Johnson Medical School, 
New Brunswick, NJ 
Background: In-hospital mortality of acute myocardial infarction (Ml) has declined in the 
last 15 years. This study focuses on the outcome of patients after discharge. 
Methods: Using a statewide Ml database, we examined post-discharge mortality among 
30,341 Ml patients who were hospitalized in New Jersey from 1966 and 1996. 
Results: In 1996 patients were older and more likely to have non-Q MI. revascularization, 
comorbidity and shorter length of stay. Age adjusted one year mortality after discharge 
was higher in 1996 compared with 1966 (RR 1.06, 95% Cl 1.01-l .16). The increase per- 
sisted after adjustment for demographics, comorbidities, complications, procedures and 
age of infarction (RR 1.54, 95% Cl 1.42-1.67). The increased post-discharge mortality 
diminished the benefit of the marked decline of in-hospital mortality from 3.6% absolute 
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risk reduction at discharge (age-adjusted RR 0.68, 95% Cl 0.64-0.72) to 1.2% reduction 
at one year after the MI (age adjusted RR 0.83, 95% Cl 0.79-0.87). These trends were 
magnified among patients with non-Q Ml. Different patient demographics, shorter length 
of stay and higher number of potentially unstable non-Q Ml’s resulting from thrombolysis 
may account for part of the increase in post discharge mortality in 1996. 
Conclusions The increased monality after discharge of MI patients in the thrombolytic era 
diminished the benefit of improved inpatient care. For each 1,000 MI admissions, 38 
more patients were discharged alive in 1996 than in 1986 while one year later only 12 
more were alive. While in-hospital mortality for non-Q MI remained lower (one fourth to 
one third) than that of Cl Ml from 1986 to 1996. the one year mortality for non-Q Ml was 
the same as Q Ml in 1996. 
1126-101 Cytomegalovirus: Strength of Antibody Response and 
Its Relationship to Risk of Mortality Among Patients 
With Angiographic Coronary Disease 
Beniamin D. Home, Joseph B. Muhlestein. John F. Carlquist. Dale G. Renlund. Tami L. 
Bair, Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake 
City, UT 
Background: IgG seropositivity to cylomegalovirus (CMV) has been shown in a variety 
of studies to predict future outcome in patients with coronary heart disease (CHD). 
Seropositivity is usually defined by an arbitrary threshold of antibody response. However, 
among CHD patients, whether the strength of antibody response to CMV infection is pra- 
dictive of future outcome is unknown. 
Methods The Registry of the Intermountain Heart Collaborative Study provided a cohort 
of consenting patients (N=2,797) with significant, angiographically-defined atherosclero- 
sis. CMV IgG serology was measured as an immune status ratio (ISR) value by ELISA 
(manufacturer’s criterium for seropositivity is ISR=l.l). Patients were followed for up to 
7.9 years (mean: 3.3r2.0 years) to determine the incidence of all-cause moltality. The 
predictive value for mortality of the continuous distribution of ISR levels was evaluated 
compared to slmpk seropositivity Cox regression adjusted for 24 demographics, CHD 
risk factors, comorbidities, and treatments. 
Results Average age was 65+11 years: 76% were male. A significant linear association 
with mortality was found for the continuous ISR values (hazard ratio (HR]=l.O9/ISR unit, 
p&001). Recursive partitioning confirmed the manufacturer’s threshold for seropositivily 
as an appropriate decision point for CHD risk (seronegative: death=lO%; seropositive: 
death=l9%; fully adjusted Cox: p=O.O16, HR=1.3. 95% CI=l.l-1.7). However, among 
seropositive patients it also revealed a second threshold (ISR=3.76) above which the risk 
of moltality was ameliorated, with death=22% for ISR=l.l-3.76 (n=964, p=O.O38 vs. 
seronagatlve, HR=l.4, Cl=l.O2-1.8) and death=l6% for ISR>3.76 (n=1168, p=O 30 vs. 
seronegative, H&1.2, CI=O.67-1.6). 
Conclusions In this large population of patients with coronary disease at baseline, CMV 
seropositivity was significantly predictive of future mortality. However, the risk was great- 
est for intermediate antibody levels and was ameliorated at higher levels. This raises new 
questions about the nature and complexity of the host immunologic response to CMV 
exposure and how it relates to determination of CHD risk. 
1126-l 02 Is COX-2 Inhibitor Use Associated With an Increased 
Rate of Recurrent Events Among Patients With a Recent 
Cardiovascular Event? 
Roberto A. Corws, Jr, John House, Nancy Drummond, William H. Downham. Steven P. 
Marso, Mid America Heart Institute, Kansas City, MO 
Backaround: Retrospective m&a-analyses have suggested that cyclooxygenase-2 
inhibitor (COX-2) use is associated with an increased risk of thrombotic cardiovascular 
events. 
Methods Patients hospitalized for an initial cardiovascular event (N-2876) were identi- 
fied from a large HMO database usmg specific ICD-9 codes for acute MI, unstable 
angina, or stroke (CVA). Patients with a prior history of cardiovascular or cerebrovascular 
disease were excluded from this analysis. Based on prescription data. patients were sub- 
divided based on active COX-2 use subsequent to the initial cardiovascular event. The 
primary endpoint of this study was the occurrence of cardiovascular mortality, re-infarc- 
tion, CVA, or acute peripheral arterial occlusion wthin one year of the primaly event. 
Regultg There were no significant demographic differences between pabents with 
(N=l70) and without (N=2706) COX-2 use Rates of recurrent cardiovascular events are 
demonstrated below: 
Conclusionr COX-2 use does not confer an increased risk of recurrent events following 
an initial cardiovascular event. Further prospective randomized trials are needed to con- 
firm these findings. 
1126-103 Predicting Early Coronary Revasculariration After an 
Acute Coronary Syndrome 
Jeffrev A. Gavard Bernard R. Chaitman, Shunta Sakai, Karen Stocke, Nicolas Danchin, 
Leif Erhardt. Eric Chi. Andreas Jessel, Richard Gallo, Pierre Theroux, for the GUARDIAN 
Investigators, St. Louis University School of Medicine, St. Louis, MO 
Background: Risk models to predict coronary revascularization (REVASC) within 6 
weeks after an acute coronary syndrome (ACS) may facilitate earlier triage. 
Methods: The GUARDIAN trial contained 4,233 ACS pts without persistent ST elevation. 
Baseline and post-randomization variables were compared between pts with and without 
REVASC. A multivariate logistic regression model was used to develop a REVASC risk 
score. 
Results: REVASC occurred in 1,239 (29.3%) pts. Final multivariate results (table). The 
6-week REVASC risk was 17.6%. 32.8%. and 46.0% for pts with risk scores ~3~4-5. and 
z6, respectively (p<O.OOl); 37.3%, 47.3%, and 15.3% of the pts were in each group. 
Conclusions: Risk scores identify ACS pts at higher risk for REVASC and may assist in 
early triage procedures. 
Univariate Analysis 
With Factor Without Factor 
Risk Factor 
Age ~65 
Male gender 
Multiracial 
N REVASC N REVASC 
(%) (%) 
2.03 32.5 2.19 26.3 
9 4 
2,88 31.8 1.34 23.8 
6 7 
56 48.2 3.92 29.2 
” 
L 
Angina 3,28 31.0 951 23.1 
2 
No CHF 3,65 30.5 582 21.6 
Hypercholesterolem 2,14 33.1 2,08 25.3 
ia 8 5 
Prior PTCA 553 43.2 3.67 27.0 
Serial T wave 1,36 31.7 2.01 24.3 
4 4 
Serial ST elevation 312 44.9 2,Ol 24.3 
4 
Serial Q wave 137 49.6 2,01 24.3 
4 
OR = odds ratio 
Multivariate 
Analysis 
OR ~ p-value 
1.23 co.01 
1.43 co.001 
2.43 co.01 
1.49 <O.OOl 
1.59 <O.OOl 
1.35 <O.cOl 
1.79 ~0.001 
1.50 <O.ool 
2.47 <0.001 
3.22 <O.cOl 
1126-104 Prediction of Two-Year Survival and Composite 
Endpoints Using the TM-7 Risk Score Extended by N- 
Terminal Pro-Brain Natriuretic Peptide Levels 
Rudolf Jarai, Robert Jarai, Ferenc Jarai, Nelly lordanova, Walter S. Speidl. Wolfgang 
Woloszczuk, Georg Geyer, Johann Wojta, Kurt Huber, University of Vienna, Vienna, 
Austria. Ludwig Boltzmann Institute for Experimental Endocrinology, Vienna, Austria 
Background: The TIMI- Risk Score is a useful risk stratification tool for identifvino , - 
patieits with unstable angina. The Brain Natriuretic Peptide (BNP) and the N-terminal 
fraament of it’s orohormone (N-terminal Brain Natriuretic Peotide. NBNP1 are strono. 
“. 
independent predictors of death in patients with acute myocardial infarction and unstable 
coronary disease. However, there exists at present no scoring system for the assess- 
ment of patient’s risk that combines clinical risk scores with one of these natriuretic pep- 
tides. 
Patients and methods: Plasma levels of the NBNP were determined in 145 consecutive 
patients (unstable angina and non-ST-elevation myocardial infarction; UA/NSTEMI) 
admitted to our clinic and were divided into three risk arouos accordina to their TIMI- 
score: high (6-7), medium (4-5) and low risk (l-3). With assistance of the data mining 
techniaue. decision tree (SPSS Inc.. USA). we extended these TIMI Risk orouos with the . 
patients NBNP levels. The so developed combined sconng system consists of 4 groups: 
very high (NBNP>O.G nmol/l), high (TIMI high or TIMI medium risk group and NBNP>0.33 
nmolll), medium (TIMI medium or TIMI low risk group and NBNP>0.33 nmolll) and low 
(TIMI low risk group). 
Results: The relatwe risk of death in the TIMI high, medium and low risk groups was 
30%, 10% and 2%, respectively (p<O.OOl, for trend). If the NBNP level was higher than 
0.33 nmolll (75 percentile) the relative risk of the TIMI groups increased to 44% in the 
high, to 31% in the medium and to 10% in the low risk group. If the NBNP level was 
below this cut-off level, the relative risk of death was 24%, 4% and ~1% in the respective 
TIMI groups. The relative risk of death in the combined TIMI-NBNP groups was 47%, 
20% 4%. and 1%. respectively (p<O.O005, for trend). The receiver operatmg characteris- 
tic (ROC) curve analysis for suwival was performed to test and to compare the predictive 
accuracy of the respective scoring systems. The area under the ROC-curve was 0.77 for 
